HCT resulted in a lower risk of death among patients with high risk disease or if performed shortly after diagnosis, according to an observational study.
Population-based study evaluated survival outcomes for patients with cancer diagnosed over a 41-year period.
Researchers examined data from patients who were treated for Hodgkin lymphoma between 2009 and 2013 who had received radiation therapy as part of their treatment.
Among some patients with myelodysplastic syndrome, gene expression signatures appear to be predictive of response and primary resistance to azacitidine.
Cancer incidence trends across 41 countries demonstrated sharp increases and decreases in certain cancer types over the last 15 years.
SBRT of all known metastatic sites was associated with improved PFS and OS among children and young adult patients with inoperable sarcoma.
A recent analysis of insurance claims data revealed trends in ED visits, ICU visits, hospitalizations, and antineoplastic treatment at the end of life in this population.
Nearly half of all relapses occurred within the first month of CAR-T infusion.
Peripheral T-cell lymphoma is characterized by extensive epigenetic dysregulation.
Loncastuximab tesirine is an antibody drug conjugate composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine dimer cytotoxin.
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
With the exception of alloSCT and iron chelation therapy, many guideline treatments may not improve survival among patients with myelodysplastic syndrome.
The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Two VA medical centers were each awarded one-time $50,000 grant funding to help them enroll veterans with cancer into clinical trials.